Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Feb 26 2026

Full Issue

Research Roundup: The Latest Science, Discoveries, And Breakthroughs

Each week, Ñî¹óåú´«Ã½Ò•îl Health News compiles a selection of health policy studies and briefs.

A blood test for detecting cancer early being developed by the diagnostics firm Grail failed to meet its main goal in a giant study being conducted with England’s National Health Service, the company said Thursday. (Herper and Chen, 2/19)

A novel single-tablet regimen (STR) combining the drugs bictegravir and lenacapavir provided similar viral suppression as multi-pill antiretroviral therapy among older adults with HIV, according to a phase 3 clinical trial published today in The Lancet. The STR also increased treatment satisfaction among participants for 48 weeks of follow-up, or about 11 months. (Bergeson, 2/25)

A large 9-year Korean study showed that current smoking status, not historical use, was the primary driver behind a reduced risk of Parkinson's disease. (George, 2/25)

University of Maryland researchers found that watching someone get relief from pain in a video can have pain-relieving effects. (Hille, 2/23)

A selective strategy for calcium supplementation after total thyroidectomy was just as safe and effective as blanket routine supplementation, and spared some patients from potentially unnecessary medication, a randomized trial showed. (Monaco, 2/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
  • Thursday, May 21
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF